Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Collegium, the most common co-covered peer. Vericel appears in 1 tracked Biotech story from February 26, 2026. The tracked stories average 12 original sources each.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Collegium, the most common co-covered peer. Vericel appears in 1 tracked Biotech story from February 26, 2026. The tracked stories average 12 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vericel. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Vericel is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
